Anixa Biosciences, Inc.
$3
▼
-6.25%
2026-04-21 05:19:00
www.anixa.com
NCM: ANIX
Explore Anixa Biosciences, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$100.58 M
Current Price
$3
52W High / Low
$5.46 / $2.44
Stock P/E
—
Book Value
$0.45
Dividend Yield
—
ROCE
-82.91%
ROE
-68.06%
Face Value
—
EPS
$-0.32
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
4
Beta
0.58
Debt / Equity
1.39
Current Ratio
12.18
Quick Ratio
8.08
Forward P/E
-7.27
Price / Sales
—
Enterprise Value
$74.95 M
EV / EBITDA
—
EV / Revenue
—
Rating
Strong Buy
Target Price
$10.75
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Coeptis Therapeutics Holdings, Inc. | $15.54 | — | $91.17 M | — | -90.67% | -1.37% | $21.41 / $6.26 | $2.36 |
| 2. | Rapport Therapeutics, Inc. | $37.14 | — | $1.9 B | — | -25.36% | -28.22% | $42.27 / $7.73 | $10.14 |
| 3. | Alto Neuroscience, Inc. | $27.33 | — | $885.53 M | — | -38.28% | -41.8% | $28.11 / $2.09 | $4.74 |
| 4. | Revolution Medicines, Inc. | $143.09 | — | $30.24 B | — | -57.28% | -58.07% | $155.7 / $34 | $8.28 |
| 5. | Regeneron Pharmaceuticals, Inc. | $753.59 | 17.99 | $79.36 B | 0.5% | 10.23% | 14.86% | $821.11 / $476.49 | $304.65 |
| 6. | Aardvark Therapeutics, Inc. | $5.65 | — | $114.1 M | — | -58.82% | -64.44% | $17.94 / $3.35 | $4.89 |
| 7. | Senti Biosciences, Inc. | $1.14 | — | $34.26 M | — | -171.08% | -2.18% | $5.1 / $0.77 | $0.18 |
Quarterly Results
Figures shown in M / B
| Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — | — |
| Operating Profit | -2.72 M | -2.88 M | -2.44 M | -3 M | -3.39 M | — | — |
| Net Profit | -2.56 M | -2.69 M | -2.26 M | -2.79 M | -3.18 M | — | — |
| EPS in Rs | -0.08 | -0.08 | -0.07 | -0.08 | -0.09 | — | -0.1 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0.21 M | 0 M |
| Operating Profit | -11.7 M | -13.83 M | -11.01 M | -13.88 M |
| Net Profit | -10.93 M | -12.55 M | -9.81 M | -13.6 M |
| EPS in Rs | -0.33 | -0.37 | -0.29 | -0.41 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 16.08 M | 21.59 M | 25.52 M | 30.41 M |
| Total Liabilities | 2.13 M | 2.7 M | 2.15 M | 2.21 M |
| Equity | 15.16 M | 20 M | 24.34 M | 29.05 M |
| Current Assets | 15.89 M | 21.36 M | 25.36 M | 30.2 M |
| Current Liabilities | 1.97 M | 2.5 M | 2.03 M | 2.04 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -7.17 M | -7.33 M | -6.21 M | -6.49 M |
| Investing CF | 4.87 M | 4.28 M | -5.6 M | -10.73 M |
| Financing CF | 2.28 M | 3.42 M | 0.37 M | 0.45 M |
| Free CF | -7.17 M | -7.33 M | -6.21 M | -6.49 M |
| Capex | — | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -100% | — | — | — |
| Earnings Growth % | -27.96% | 27.83% | — | — |
| Profit Margin % | — | -4671.9% | — | — |
| Operating Margin % | — | -5243.33% | — | — |
| Gross Margin % | — | 23.33% | — | — |
| EBITDA Margin % | — | -5221.43% | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.